AIR: No Impact of Switching From 3-Drug to 2-Drug ART on Adverse Disease Outcomes in Virologically-Suppressed Persons With HIV

Clinical Care Options (CCO) commentary from Dr Darrell Tan on the dosing options for long-acting injectable cabotegravir plus rilpivirine for HIV treatment

Babafemi Taiwo, MBBS
Program Director Darrell H. S. Tan, MD, FRCPC, PhD Released: August 12, 2022

Drs. Jean Rene Anderson and William Short speak to the balancing act when considering HIV treatments during pregnancy, from Clinical Care Options (CCO)

Jean Rene Anderson, MD William R. Short, MD, MPH, AAHIVS Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: August 12, 2022 Expired: August 11, 2023

Opciones de cuidado clínico (CCO) presenta a la Dra. Alicia Piñeirúa que explica los principales factores que hay que tener en cuenta a la hora de optimizar el tratamiento antirretroviral en el marco de la supresión viral en pacientes que viven con el VIH y la osteopenia

Alicia Piñeirúa Menéndez, MD, MPH Released: August 2, 2022

SIMPL’HIV: switch from standard ART to DTG + FTC in virologically suppressed PWH through Wk 144, reported by Clinical Care Options (CCO) from AIDS 2022